Celldex Therapeutics
Our lead program barzolvolimab is a humanized monoclonal antibody inhibitor of KIT, a key receptor tyrosine kinase required for the function and survival of mast cells, which play a central role in the onset and progression of many severe inflammatory, allergic and autoimmune diseases. By targeting a core pathological driver of these diseases, we have designed barzolvolimab with the potential to be a best-in-class treatment option and improve the lives of patients. Driven by our deep and longsta
Basic Information
- Category: Vaccines
- Founded: 1983
- Headquarters: Hampton, NJ
- Website: celldex.com
Documented Facts
- Phone: (908) 454-7120 (No linked source recorded for this statement.)
- Email: info@celldex.com (No linked source recorded for this statement.)
- Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
- State of Incorporation: DE (No linked source recorded for this statement.)
- Stock ticker: CLDX (Nasdaq) (No linked source recorded for this statement.)
Evidence and Sources
- Celldex Therapeutics — Official Site (official)
- Celldex Therapeutics on linkedin (social)
- Celldex Therapeutics, Inc. — SEC EDGAR (reference)
Citation Guidance
Explore Vaccines profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Celldex Therapeutics.
- Canonical profile: https://brandsource.ai/brands/celldex-therapeutics
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/celldex-therapeutics/json-ld
- Citation profile API: https://brandsource.ai/api/brands/celldex-therapeutics/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (94/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-27T08:35:04.747Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Our lead program barzolvolimab is a humanized monoclonal antibody inhibitor of KIT, a key receptor tyrosine kinase required for the function and survival of mast cells, which play a central role in the onset and progression of many severe inflammatory, allergic and autoimmune diseases. By targeting a core pathological driver of these diseases, we have designed barzolvolimab with the potential to be a best-in-class treatment option and improve the lives of patients. Driven by our deep and longsta
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 5 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.